Compared to placebo, antiembolic therapies including NOACs, VKA, aspirin, and the Watchman device significantly reduced stroke or systemic embolism in nonvalvular AF (ORs ranging from 0.27 to 0.75).
Meta-Analysis (n=96,017)
Do antiembolic interventions (NOACs, VKA, aspirin, Watchman device) reduce stroke and systemic embolism in patients with nonvalvular atrial fibrillation?
A network meta-analysis demonstrates that NOACs, VKA, aspirin, and the Watchman device all significantly reduce the risk of stroke, systemic embolism, and all-cause mortality compared to placebo or control in patients with nonvalvular atrial fibrillation.
Effect estimate: OR 0.27-0.75 (95% CI 0.16-0.95)
BACKGROUND: The goal of this study was to compare the safety and effectiveness of individual antiembolic interventions in nonvalvular atrial fibrillation (AF): novel oral anticoagulants (NOACs) (apixaban, dabigatran, edoxaban, and rivaroxaban); vitamin K antagonists (VKA); aspirin; and the Watchman device. METHODS AND RESULTS: A network meta-analysis of randomized, clinical trials (RCTs) was performed. RCTs that included patients with prosthetic cardiac valves or mitral stenosis, mean or median follow-up <6 months, <200 participants, without published report in English language, and NOAC phase II studies were excluded. The placebo/control arm received either placebo or no treatment. The primary efficacy outcome was the combination of stroke (of any type) and systemic embolism. All-cause mortality served as a secondary efficacy outcome. The primary safety outcome was the combination of major extracranial bleeding and intracranial hemorrhage. A total of 21 RCTs (96 017 nonvalvular AF patients; median age, 72 years; 65% males; median follow-up, 1.7 years) were included. In comparison to placebo/control, use of aspirin (odds ratio OR, 0.75 95% CI, 0.60-0.95), VKA (0.38 0.29-0.49), apixaban (0.31 0.22-0.45), dabigatran (0.29 0.20-0.43), edoxaban (0.38 0.26-0.54), rivaroxaban (0.27 0.18-0.42), and the Watchman device (0.36 0.16-0.80) significantly reduced the risk of any stroke or systemic embolism in nonvalvular AF patients, as well as all-cause mortality (aspirin: OR, 0.82 0.68-0.99; VKA: 0.69 0.57-0.85; apixaban: 0.62 0.50-0.78; dabigatran: 0.62 0.50-0.78; edoxaban: 0.62 0.50-0.77; rivaroxaban: 0.58 0.44-0.77; and the Watchman device: 0.47 0.25-0.88). Apixaban (0.89 0.80-0.99), dabigatran (0.90 0.82-0.99), and edoxaban (0.89 0.82-0.96) reduced risk of all-cause death as compared to VKA. CONCLUSIONS: The entire spectrum of therapy to prevent thromboembolism in nonvalvular AF significantly reduced stroke/systemic embolism events and mortality.
Tereshchenko et al. (Fri,) conducted a meta-analysis in nonvalvular atrial fibrillation (n=96,017). Antiembolic interventions (NOACs, VKA, aspirin, Watchman device) vs. Placebo or no treatment was evaluated on Combination of stroke (of any type) and systemic embolism (OR 0.27-0.75, 95% CI 0.16-0.95). Compared to placebo, antiembolic therapies including NOACs, VKA, aspirin, and the Watchman device significantly reduced stroke or systemic embolism in nonvalvular AF (ORs ranging from 0.27 to 0.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: